ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

ClinicalTrials.gov ID: NCT04457336

Public ClinicalTrials.gov record NCT04457336. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects With Classic Congenital Adrenal Hyperplasia

Study identification

NCT ID
NCT04457336
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Spruce Biosciences
Industry
Enrollment
96 participants

Conditions and interventions

Interventions

  • Tildacerfont/Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 25, 2020
Primary completion
Feb 8, 2024
Completion
May 22, 2024
Last update posted
Jul 7, 2025

2020 – 2024

United States locations

U.S. sites
28
U.S. states
17
U.S. cities
27
Facility City State ZIP Site status
Spruce Study Site Birmingham Alabama 35294
Spruce Study Site Los Angeles California 90027
Spruce Clinical Site Orange California 92868
Spruce Study Site Sacramento California 95817
Spruce Study Site Englewood Colorado 80113
Spruce Clinical Site Tampa Florida 33612
Spruce Study Site West Palm Beach Florida 33401
Spruce Study Site Chicago Illinois 60611
Spruce Clinical Site Indianapolis Indiana 46202
Spruce Study Site Baltimore Maryland 21287
Spruce Clinical Site Minneapolis Minnesota 55454
Spruce Study Site Rochester Minnesota 55905
Spruce Clinical Site Las Vegas Nevada 89148
Spruce Study Site Hickory North Carolina 28601
Spruce Study Site Canton Ohio 44718
Spruce Study Site Cincinnati Ohio 45219
Spruce Study Site Cleveland Ohio 44195
Spruce Study Site Columbus Ohio 43210
Spruce Clinical Site Bend Oregon 97702
Spruce Study Site Philadelphia Pennsylvania 19104
Spruce Study Site Philadelphia Pennsylvania 19107
Spruce Study Site Providence Rhode Island 02903
Spruce Study Site Columbia South Carolina 28203
Spruce Clinical Site Memphis Tennessee 38163
Spruce Study Site Austin Texas 78731
Spruce Study Site Dallas Texas 75093
Spruce Clinical Site Edinburg Texas 78539
Spruce Clinical Site Fort Worth Texas 76104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04457336, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 7, 2025 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04457336 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →